Xenon Pharmaceuticals is in the biotechnology industry and healthcare sector. The company CEO is Simon Pimstone. Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its products portfolio includes Glybera, TV-45070.
Previous Intraday Performance:
The XENE shares had a previous change of 1.00% which opened at 9.02 and closed at 9.06. It moved to an intraday high of 9.15 and a low of 8.97.
Over the last five trading days, XENE shares returned -12.63% and in the past 30 trading days it returned 2.26%. Over three months, it changed -1.74%. In one year it has changed 31.30% and within that year its 52 week high was 15.92 and its 52 week low was 5.41. XENE stock is 67.47% above its 52 week low.
Our calculations result in a 200 day moving average of 9.54 and a 50 day moving average of 9.56. Right now, XENE stock is trading -5.03% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.
The company has a market cap of $233.5m with 25.8m shares outstanding and a float of 25.1m shares. Trading volume was 31,611 shares and has experienced an average volume of 101,348 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
The last annual reported EPS for Xenon Pharmaceuticals was -1.58 which ended on 31st of December 2018. Based on 2 analyst estimates, the consensus EPS for the next quarter is -0.36.
Below was the last reported quarterly diluted earnings per share:
|1st||Qtr 2019||Reported 05-07-2019:||-0.42|
|4th||Qtr 2018||Reported 03-06-2019:||-0.29|
|3rd||Qtr 2018||Reported 11-06-2018:||-0.63|
|2nd||Qtr 2018||Reported 08-07-2018:||-0.45|
|1st||Qtr 2018||Reported 05-08-2018:||-0.21|
The long-term trend of the EPS is an important number as it indicates the present value of Xenon Pharmaceuticals; the EPS growth rate, as it is usually called, is typically displayed as a percentage, which at this time is hard to estimate, but revenue growth has been -100.00% over the last twelve months.
Indicators Also to Watch:
Based on the latest filings, there is 96.80% of institutional ownership.
The beta was calculated to be 1.33.
Based on last reported financials, the company’s return on assets is -52.11% and price-to-book is 2.73.
Company Score Card:
Results are out of six:
5 : Growth Expectations Result
5 : Financial Safety Result
0 : Past Performance Result
1 : Valuation Result
0 : Dividend Safety Result
2 : Overall Result